Dr. Bannerji on the Toxicity Profile of Odronextamab in Non-Hodgkin Lymphoma

Partner | Cancer Centers | <b>Rutgers Cancer Institute of New Jersey</b>

Rajat Bannerji, MD, PhD, discusses the toxicity profile of odronextamab in non-Hodgkin lymphoma.

Rajat Bannerji, MD, PhD, hematologist/oncologist and chief of hematologic malignancies at the Rutgers Cancer Institute of New Jersey, discusses the toxicity profile of odronextamab (REGN1979) in non-Hodgkin lymphoma (NHL).

During the 2020 ASH Annual Meeting & Exposition, the study schema of an ongoing phase 2 trial (NCT03888105) of odronextamab, a CD20 x CD3 bispecific antibody, in patients with relapsed/refractory B-cell NHL was presented virtually. Previously reported data demonstrated encouraging antitumor activity and manageable toxicity with odronextamab among this patient population.

To date, safety signals with odronextamab include low-grade cytokine release syndrome and low-grade central nervous system toxicities, explains Bannerji. Notably, these toxicities tend to appear early in the treatment course. Other higher-grade toxicities, including infection, were observed and could present later, Bannerji says. However, very late-onset toxicities were not observed among patients who received odronextamab and remain in remission and off-treatment for over 1 year, concludes Bannerji.